Table 1 Demographic and Clinical Measures of Study Participants
ID | Diagnosis | Age | Sex | Duration of disease (years) | Previous Medications | Change in UPC | Serum albumin (mg/dl) | # Relapses in previous 12 months | # Relapses during taVNS study | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Â | Â | Baseline | 6 months | Â | Â | |
001 | FRNS | 4 | M | 1.5 | - | - | - | 3 | 0 | ||
002 | 8 | M | 5 | MMF | - | - | 4 | 0 | |||
003 | 8 | M | 4 | MMF | - | - | 4 | 0 | |||
004 | SRNS: FSGS | 7 | M | 2.7 | tacrolimus, enalapril, prednisolone | -76% | 3.3 | 3.3 | - | - | |
005 | 11 | F | 3.8 | tacrolimus, enalapril, prednisolone | -36% | 4.7 | 4.8 | - | - | ||
006 | 17 | F | 3.3 | tacrolimus, enalapril, prednisolone | -25% | 4.5 | 4.6 | - | - | ||
007 | SRNS: Congenital Nephrotic | 12 | F | 12 | tacrolimus, enalapril, losartan prednisolone | -13.7% | 2.5 | 2.4 | - | - | |